R&D
"The overall development pipeline structure of NeoImmuneTech."
The composition of the T cell-centered pipeline.
NT10 (NT-I7) is a T Cell Amplifier designed to enhance T cell responses and is being developed for the treatment of cancer and various immune-related diseases.
NT20 is being developed as a T Cell Activator that stimulates T cells by targeting specific components within them.
NT30 is a T Cell Engager that facilitates the connection between T cells and target cancer cells, enabling T cells to effectively attack and eliminate cancer cells. By leveraging our self-developed NEOBASE platform, we aim to develop products that surpass the capabilities of conventional T cell engagers.
NT40 is an advanced CAR-T therapy under development, specifically designed to overcome the challenges posed by the tumor microenvironment in solid cancers, which can impede the effectiveness of existing CAR-T therapies.
NT50, known as the TME Modifier aims to modify the tumor microenvironment (TME). By altering the TME, we intend to create an environment that enables T cells, crucial players in anti-cancer immunity, to exert a stronger and more effective anti-cancer response within the tumor.
NT20 is being developed as a T Cell Activator that stimulates T cells by targeting specific components within them.
NT30 is a T Cell Engager that facilitates the connection between T cells and target cancer cells, enabling T cells to effectively attack and eliminate cancer cells. By leveraging our self-developed NEOBASE platform, we aim to develop products that surpass the capabilities of conventional T cell engagers.
NT40 is an advanced CAR-T therapy under development, specifically designed to overcome the challenges posed by the tumor microenvironment in solid cancers, which can impede the effectiveness of existing CAR-T therapies.
NT50, known as the TME Modifier aims to modify the tumor microenvironment (TME). By altering the TME, we intend to create an environment that enables T cells, crucial players in anti-cancer immunity, to exert a stronger and more effective anti-cancer response within the tumor.
R&D Pipeline
| Project | Pipeline | Indication | Development Status | ||
|---|---|---|---|---|---|
| DISCOVERY | Preclinical | Clinical | |||
| NT2020 | T cell Activator (PROTAC) |
Undisclosed | |||
| NT3020 | T cell Engager (CD3xTAA) |
Solid tumors | |||
| NT4010 | Advanced CAR-T | Solid tumors | |||
| NT5010 | TME Modifier (eTreg depletor) |
Solid tumors | |||